![Public 1](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/public-1/9144114-1-eng-GB/public-1_i770.jpg)
Preclinical research offers promise of new CDK4/6 inhibitors
Positive in vitro and in vivo antitumour effects in breast and lung cancer models and in mismatch repair-driven cancer models
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.